Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
Ibrutinib and lenalidomide: When 111 5 .2
Jason Westin
Lymphoma-Myeloma
Research output
:
Contribution to journal
›
Review article
›
peer-review
4
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ibrutinib and lenalidomide: When 111 5 .2'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
PCI 32765
82%
Lenalidomide
73%
Lymphoma, Large B-Cell, Diffuse
62%
Rituximab
60%
Therapeutics
9%
Chemistry
Lenalidomide
100%
Ibrutinib
99%